NASDAQ: AMRNAmarin Corp PLC Stock
$16.03+0.26 (+1.65%)
Updated Jun 18, 2026
AMRN Price
$16.03
Fair Value Price
-$13.99
Market Cap
$336.13M
52 Week Low
$12.30
52 Week High
$20.90
P/E
-10.02x
P/B
0.75x
P/S
1.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$216.76M
Earnings
-$33.61M
Gross Margin
52.4%
Operating Margin
-14.15%
Profit Margin
-15.5%
Debt to Equity
0.44
Operating Cash Flow
$26M
Beta
1.12
Next Earnings
Jul 29, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AMRN Overview
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AMRN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
AMRN
Ranked#12 of 16
Ranked#12 of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $1,098.57 | A | |
| $174.93 | B | |
| $54.00 | B |
Be the first to know about important AMRN news, forecast changes, insider trades & much more!
AMRN News
Overview
Due Diligence Score
–
Industry Average (36)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AMRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMRN ($16.03) is overvalued by 214.56% relative to our estimate of its Fair Value price of -$13.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AMRN ($16.03) is not significantly undervalued (214.56%) relative to our estimate of its Fair Value price of -$13.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AMRN due diligence checks available for Premium users.
Valuation
AMRN fair value
Fair Value of AMRN stock based on Discounted Cash Flow (DCF)
Price
$16.03
Fair Value
-$13.99
Undervalued by
214.56%
AMRN ($16.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMRN ($16.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AMRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.02x
Industry
36.29x
Market
9.47x
AMRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.75x
Industry
7.04x
AMRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMRN's financial health
Profit margin
Revenue
$62.3M
Net Income
-$48.6M
Profit Margin
-78%
AMRN's Earnings (EBIT) of -$30.68M... subscribe to Premium to read more.
Interest Coverage Financials
AMRN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$685.3M
Liabilities
$199.2M
Debt to equity
0.41
AMRN's short-term assets ($626.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMRN's short-term assets ($626.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMRN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AMRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.3M
Investing
-$22.8M
Financing
$17.0k
AMRN's operating cash flow ($25.58M)... subscribe to Premium to read more.
Debt Coverage Financials
AMRN vs General Drug Manufacturer Stocks
Amarin Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.